Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab plus platinum-based chemotherapy as first-line treatment for advanced or recurrent non-squamous non-small cell lung cancer
2005-005887-97Phase 3Completed
- Sponsor
- Roche
- Start
- Jun 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of bevacizumab in non-small cell lung cancer (NSCLC), sponsored by Roche. Primary endpoints: Incidence of serious adverse events related to bevacizumab and Incidence of specific adverse events. Started Jun 2006; status: completed.
02
Drugs
bevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2005-005887-97.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005887-97.